TurkmenistanTuberculosis profile
Population  2014 5.3 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.18 (0.15–0.21) 3.4 (2.9–4)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 4.7 (2.2–8.2) 88 (41–154)
Incidence  (includes HIV+TB) 3.4 (2.7–4.1) 64 (52–78)
Incidence (HIV+TB only)        
         
Case detection, all forms (%) 76 (62–94)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 14 (11–17) 38 (30–45)
MDR-TB cases among notified pulmonary
TB cases
270 (220–330) 180 (150–220)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 944   173
Pulmonary, clinically diagnosed      
Extrapulmonary 415   38
       
Total new and relapse 2 570    
Previously treated, excluding relapses 317    
Total cases notified 2 887    
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 310 (16%) 162 (31%) 354
Laboratory-confirmed RR-/MDR-TB cases     210
Patients started on MDR-TB treatment ***     210
TB/HIV 2014 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (72) 3 046
Previously treated cases registered in 2013 (26) 629
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 3.8
Drug susceptibility testing (per 5 million population) 2.8
Sites performing Xpert MTB/RIF 6
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) <1
% Funded domestically  
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-29 Data: www.who.int/tb/data